Clinical trial
Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With…
NCT00030186 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00030186 |
|---|---|
| Title | Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation |
| Official title | An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid |
| Intervention type | Drug |
| Interventions | CEP-701 60mg, Cep-701 80mg, Cep-701 40mg |
| Enrollment | 37 |
| Start date | Jan 1, 2002 |
| Primary completion | Feb 1, 2003 |
| Completion | Feb 1, 2003 |
| First posted | Feb 8, 2002 |
| Last update posted | Aug 23, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: